相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II study of modified FOLFIRINOX for chemotherapy-na < ve patients with metastatic pancreatic cancer
Masato Ozaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Y. Yamada et al.
ANNALS OF ONCOLOGY (2018)
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma
Hiroaki Yanagimoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
P-122Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for Unresectable pancreatic ductal adenocarcinoma
M. Sasaki et al.
ANNALS OF ONCOLOGY (2016)
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stacey M. Stein et al.
BRITISH JOURNAL OF CANCER (2016)
Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER SCIENCE (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro et al.
LANCET ONCOLOGY (2010)
分享论文
